Antoine Schernberg1, Alexandre Escande1, Eleonor Rivin Del Campo1, Michel Ducreux2, France Nguyen1, Diane Goere3, Cyrus Chargari4, Eric Deutsch5. 1. Radiotherapy Department, Gustave Roussy Cancer Campus, Villejuif, France. 2. Université Paris Sud, Université Paris Saclay, Faculté de médecine du Kremlin-Bicetre, Le Kremlin-Bicetre, France; Department of Medical Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France. 3. Department of Surgery, Gustave Roussy, Université Paris-Saclay, Villejuif, France. 4. Radiotherapy Department, Gustave Roussy Cancer Campus, Villejuif, France; INSERM1030, Gustave Roussy Cancer Campus, Villejuif, France; French Military Health Services Academy, Ecole du Val-de-Grâce, Paris, France; Institut de Recherche Biomédicale des Armées, Bretigny-sur-Orge, France. 5. Radiotherapy Department, Gustave Roussy Cancer Campus, Villejuif, France; Université Paris Sud, Université Paris Saclay, Faculté de médecine du Kremlin-Bicetre, Le Kremlin-Bicetre, France; INSERM1030, Gustave Roussy Cancer Campus, Villejuif, France. Electronic address: eric.deutsch@gustaveroussy.fr.
Abstract
OBJECTIVE: Leukocytosis and neutrophilia could be the tip of the iceberg in the inflammatory tumor microenvironment. We aimed to validate their prognostic significance in a cohort of patients treated with definitive chemoradiation for anal squamous cell carcinoma (SCC). MATERIALS & METHODS: Clinical records from all consecutive patients treated in a single institution between 2006 and 2016 with curative-intent radiotherapy were retrospectively analyzed. Leukocytosis and neutrophilia, defined as leukocyte or neutrophil count over 10,000 and 7500/mm3, respectively, were studied in terms of overall survival (OS), progression (PFS), locoregional (LFS) and distant (DFS)-free survival. RESULTS: We identified 103 non-metastatic HIV-negative patients, with concurrent chemotherapy use in 78%. Twelve and 8% displayed baseline leukocytosis and neutrophilia, respectively. Estimated 3-year OS and PFS were 88% and 67%, respectively. In univariate analysis, both leukocytosis and neutrophilia were strongly associated with inferior OS, PFS, LFS and DFS (p<0.01). In multivariate analysis, leukocytosis and neutrophilia remained strongly associated with patient outcome (p<0.01), independently from tumor T and N-stage. Anemia was an independent predictor of worse OS and PFS, while chemoradiation overall treatment time below 50days improved PFS. CONCLUSION: Leukocytosis and neutrophilia are strong prognostic factors for OS, PFS, LFS and DFS in anal cancer treated with chemoradiation. These biomarkers could help identify patients with higher risk of tumor relapse that require treatment intensification.
OBJECTIVE:Leukocytosis and neutrophilia could be the tip of the iceberg in the inflammatory tumor microenvironment. We aimed to validate their prognostic significance in a cohort of patients treated with definitive chemoradiation for anal squamous cell carcinoma (SCC). MATERIALS & METHODS: Clinical records from all consecutive patients treated in a single institution between 2006 and 2016 with curative-intent radiotherapy were retrospectively analyzed. Leukocytosis and neutrophilia, defined as leukocyte or neutrophil count over 10,000 and 7500/mm3, respectively, were studied in terms of overall survival (OS), progression (PFS), locoregional (LFS) and distant (DFS)-free survival. RESULTS: We identified 103 non-metastatic HIV-negative patients, with concurrent chemotherapy use in 78%. Twelve and 8% displayed baseline leukocytosis and neutrophilia, respectively. Estimated 3-year OS and PFS were 88% and 67%, respectively. In univariate analysis, both leukocytosis and neutrophilia were strongly associated with inferior OS, PFS, LFS and DFS (p<0.01). In multivariate analysis, leukocytosis and neutrophilia remained strongly associated with patient outcome (p<0.01), independently from tumor T and N-stage. Anemia was an independent predictor of worse OS and PFS, while chemoradiation overall treatment time below 50days improved PFS. CONCLUSION:Leukocytosis and neutrophilia are strong prognostic factors for OS, PFS, LFS and DFS in anal cancer treated with chemoradiation. These biomarkers could help identify patients with higher risk of tumor relapse that require treatment intensification.
Authors: Sara E Beltrán Ponce; Beth A Erickson; William A Hall; Meena Bedi; Michael J Martens; Malika Siker; James Thomas; Ben George; Kirk Ludwig; Carrie Peterson; Timothy Ridolfi; John M Longo Journal: J Gastrointest Oncol Date: 2022-02
Authors: Alexandra Gilbert; Ane L Appelt; Stelios Theophanous; Robert Samuel; John Lilley; Ann Henry; David Sebag-Montefiore Journal: BMC Cancer Date: 2022-06-03 Impact factor: 4.638
Authors: Aakash Keswani; Debbie Chi; Andrew J Lovy; Daniel A London; Paul J Cagle; Bradford O Parsons; Joseph A Bosco Journal: Shoulder Elbow Date: 2018-06-12
Authors: Garrett L Jensen; Pierre Blanchard; G Brandon Gunn; Adam S Garden; C David Fuller; Erich M Sturgis; Maura L Gillison; Jack Phan; William H Morrison; David I Rosenthal; Steven J Frank Journal: Clin Transl Radiat Oncol Date: 2017-11-06
Authors: Alexis Vallard; Max-Adrien Garcia; Peng Diao; Sophie Espenel; Guy de Laroche; Jean-Baptiste Guy; Majed Ben Mrad; Chloé Rancoule; David Kaczmarek; Thierry Muron; Gregoire Pigné; Jack Porcheron; Michel Peoc'h; Jean-Marc Phelip; Julien Langrand-Escure; Nicolas Magné Journal: Oncotarget Date: 2018-04-27